High seroprotection rate induced by low doses of a recombinant hepatitis B vaccine in healthy Iranian neonates

Kane, 1998, Worldwide epidemiology of hepatitis B, Soz. Paraventimed., 43, S24, 10.1007/BF02042169 Andre, 2000, Hepatitis B epidemiology in Asia, the Middle East and Africa, Vaccine, 18, S20, 10.1016/S0264-410X(99)00456-9 Amini, 1993, Seroepidemiology of hepatitis B, Delta and HIV infections in Hamadan province of Iran, J. Trop. Med. Hyg., 96, 277 Kurstak, 1993, 83 Mass, 1998, Universal hepatitis B immunization: infants and infants plus adolescent immunization, Vaccine, 16, S17 1992, Expanded Programme on Immunization, Global Advisory Group, Wkly Epidemiol. Rec., 3, 11 Kane, 1998, Status of hepatits B immunization programme in, Vaccine, 16, S104, 10.1016/S0264-410X(98)00308-9 Zannolli, 1997, Hepatitis B vaccine: current issues, Ann. Pharmacother., 31, 1059, 10.1177/106002809703100916 1991, Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: recommendations of the Immunization practices Advisory Committee ACIP, Morbid. Mortal. Weekly Rep., 40, RR-13 Bryan, 1992, Low dose intradermal and intramuscular vaccination against hepatitis B, Clin. Infect. Dis., 14, 697, 10.1093/clinids/14.3.697 Goh, 1992, Comparison of the immune response of four different doses of a yeast recombinant hepatitis B vaccine in Singapore children: a four-year follow-up study, Bull. World Health Organ., 70, 233 Canho del, 1995, Immunogenicity of two different dosages (10 and 5 μg) of recombinant DNA hepatitis B vaccine in healthy neonates, Vaccine, 12, 1323, 10.1016/S0264-410X(94)80059-9 Goldfarb, 1996, Comparison study of the immunogenicity and safety of 5 and 10 μg dosages of recombinant hepatitis B vaccine in healthy infants, Pediatr. Infect. Dis. J., 15, 764, 10.1097/00006454-199609000-00004 Duval, 2000, Comparative immunogenicity under field condition of two recombinant hepatitis B vaccines in 8–10 years old children, Vaccine, 18, 1467, 10.1016/S0264-410X(99)00422-3 Amani, 1995, Immunogenicity of a recombinant hepatitis B vaccine in Iranian neonates: high frequency of unresponsiveness independent of the carrier state of mothers, Ir. J. Med. Sci., 20, 87 Shokri, 1997, High rate of seroconversion following administration of a single supplementary dose of recombinant hepatitis B vaccine in Iranian healthy nonresponder neonates, Med. Microbiol. Immunol., 185, 231, 10.1007/s004300050035 Tan, 1990, Immunogenicity and safety of low doses of recombinant yeast-derived hepatitis B vaccine, Acta Pediatr. Scand., 49, 593, 10.1111/j.1651-2227.1990.tb11522.x Milne, 1988, Antibody response to recombinant yeast-derived hepatitis B vaccine in teenage New Zealand children, NZ Med. J., 101, 67 Davidson, 1986, Recombinant yeast hepatitis B vaccine compared with plasma-derived vaccine: Immunogenicity and effect of a booster dose, J. Infect., 13, 33 Lazizi, 1997, Selective unresponsiveness to HBsAg vaccine in newborn related with an in utero passage of hepatitis B virus DNA, Vaccine, 15, 1095, 10.1016/S0264-410X(97)00005-4 Lamelin, 1995, Lymphotropism of hepatitis B and C virus: an update and a newcomer, Int. J. Clin. Lab. Res., 25, 1, 10.1007/BF02592570 Luo, 1992, Is nonresponsiveness to hepatitis B vaccine due to latent hepatitis B virus infection?, J. Infect. Dis., 165, 777, 10.1093/infdis/165.4.777 Milich, 1990, Is a function of the secreted HBe antigen to induce immunological tolerance in utero?, Proc. Natl. Acad. Sci. USA, 87, 6599, 10.1073/pnas.87.17.6599 Chisari, 1995, Hepatitis B virus immunopathogenesis, Annu. Rev. Immunol., 13, 29, 10.1146/annurev.iy.13.040195.000333